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INTRODUCTION  
Tyrosine kinase inhibitors (TKIs) have revolutionized oncology, 
allowing for  targeted, non-toxic chemotherapy. However, these 
medications may actually have unanticipated side effects. TKIs, 
such as nilotinib, have been associated with autoimmune 
associated side-effects, including reports of peripheral and 
central nervous system demyelination1,2,3,4,.
CASE DESCRIPTION 
A 62-year-old woman with medical history significant for 
well-controlled chronic myeloid leukemia (CML) on 
maintenance nilotinib for 5 years presented with a ten day 
history of descending weakness and sensory loss, followed 
by dyspnea requiring emergent intubation. Neurologic exam 
revealed quadriparesis and areflexia with a seemingly intact 
though limited sensory exam. 
CLINICAL COURSE AND RESULTS 
Initial MRI C spine with questionable T2 abnormality at C2, 
attributed to motion
Lumbar puncture: protein 82mg/dL and 9 WBCs/uL
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CLINICAL COURSE AND RESULTS (CONT.) 
Primarily concerned for Guillain-Barre Syndrome (GBS), 
started on 2gm/kg intravenous immunoglobulin (IVIG)
Patient developed C2 sensory level. Repeat MRI C spine 
demonstrated T2 hyperintensity C2-C7 
MRI brain, aquaporin-4 antibodies, MOG antibodies, and Mayo 
clinic cerebrospinal fluid paraneoplastic and autoimmune 
panels all negative.
Reviewed case reports of nilotinib-associated demyelination. 
With oncology guidance, nilotinib discontinued. 
Patient required tracheostomy and percutaneous gastric 
feeding tube. Discharged with minimal improvement in upper 
extremities and ventilator dependence.
CONCLUSIONS 
TKIs, including nilotinib, dasatinib, and imatinib may be 
associated with demyelinating disease of the central and 
peripheral nervous system.
Demyelination may develop at any time during the treatment 
course. Pathology and deficits may not be reversible.
The mechanism is postulated to be autoimmune mediated. 
Early recognition of these potential severe side effects and 
discontinuation of therapy may improve outcomes.
It is unknown if immune-modulating therapy (IVIG or plasma 
exchange) has any impact on outcome.
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